ImpactU Versión 3.11.2 Última actualización: Interfaz de Usuario: 16/10/2025 Base de Datos: 29/08/2025 Hecho en Colombia
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia
Background Cost-effectiveness studies evaluate health technologies and help choose treatments. The current study compared dupilumab to omalizumab, mepolizumab, and benralizumab in Colombian adults with severe uncontrolled type 2 asthma.
Tópico:
Asthma and respiratory diseases
Citaciones:
3
Citaciones por año:
Altmétricas:
0
Información de la Fuente:
FuenteExpert Review of Pharmacoeconomics & Outcomes Research
